Developing proteomic biomarkers for bladder cancer: Towards clinical application

Maria Frantzi*, Agnieszka Latosinska, Leif Flühe, Marie C. Hupe, Elena Critselis, Mario W. Kramer, Axel S. Merseburger, Harald Mischak, Antonia Vlahou

*Corresponding author for this work
32 Citations (Scopus)


Clinical use of proteomic biomarkers has the potential to substantially improve the outcomes of patients with bladder cancer. An unmet clinical need evidently exists for noninvasive biomarkers, which might enable improvements in both the diagnosis and prognosis of patients with bladder cancer, as well as improved monitoring of patients for the presence of recurrence. Urine is considered the optimal noninvasive source of proteomic biomarkers in patients with bladder cancer. Currently, a number of single-protein biomarkers have been detected in urine and tissue using a variety of proteomic techniques, each having specific conceptual considerations and technical implications. Promising preclinical data are available for several of these proteins; however, the combination of single urinary proteins into multimarker panels might better encompass the molecular heterogeneity of bladder cancer within this patient population, and prove more effective in clinical use.

Original languageEnglish
JournalNature Reviews Urology
Issue number6
Pages (from-to)317-330
Number of pages14
Publication statusPublished - 12.06.2015


Dive into the research topics of 'Developing proteomic biomarkers for bladder cancer: Towards clinical application'. Together they form a unique fingerprint.

Cite this